Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors.
Future Oncol
; 19(23): 1627-1639, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-37589145
ABSTRACT
Aim:
Time to subsequent therapy (TST) is an end point that may complement progression-free survival (PFS) and overall survival (OS) in determining the treatment effect of anticancer drugs and may be a potential surrogate for PFS and OS. We systematically reviewed the correlation between TST and both PFS and OS in published phase 2/3 studies in advanced solid tumors. Materials &methods:
Trial-level correlational analyses were performed for TST versus PFS (by investigator and/or central review) and TST versus OS.Results:
Of 21 included studies, nine (43%) used 'time to first subsequent therapy or death' (TFST) as the TST end point; 11 (57%) used different definitions ('other TST end points'). There was a strong correlation between TFST and PFS by investigator (medians R2 = 0.88; hazard ratio [HR] R2 = 0.91) and TFST versus PFS by central review (medians R2 = 0.86; HRs R2 = 0.84). For TFST versus OS there was medium/poor correlation for medians (R2 = 0.64) and HRs (R2 = 0.02).Conclusion:
TFST strongly correlates with PFS, but not with OS.
In a recent study, researchers investigated how we can measure the effectiveness of cancer drugs. They focused on a specific measure called 'time to next therapy', which is the duration between two treatments patients receive. By analyzing the relationship between time to next therapy and disease progression, they discovered a strong correlation. This suggests that in the future, time to next therapy could potentially help to measure how well a cancer treatment works. However, when it comes to predicting patient survival, the relationship was not as strong. This implies that time to next therapy is not a reliable indicator of patient survival. To fully understand whether time to next therapy can effectively measure the effectiveness of anticancer drugs, further research is necessary.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias
Tipo de estudio:
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Reino Unido